ArticleTropical diseases, travel medicine and vaccines2025
Clinical, laboratory features and treatment outcomes of patients infected with Fasciola in Northern Vietnam, 2019-2023.
Article in Tropical diseases, travel medicine and vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVietnam experiences a significant occurrence of fascioliasis infection, largely due to the common practice of consuming raw vegetables. Diagnosing the fascioliasis infection remains difficult, and patients endure various long-term consequences. The purpose of this study is to describe the clinical and laboratory features, along with the treatment approaches for fascioliasis patients in Vietnam.
methodsThe study included 31 patients diagnosed with fascioliasis in Northern Vietnam between 2019 and 2023. Blood ELISA testing, fresh stool microscopy, ultrasonography, and magnetic resonance imaging were all used to evaluate the patients. The patients received triclabendazole, and the efficacy of treatment was assessed three months later.
resultsAll patients infected with Fasciola reported having raw vegetables and exhibited typical clinical symptoms of right hypochondriac pain (61%), epigastric pain (58%), exhaustion, and anorexia (42%). All patients presented with a hepatic lesion, with an average abscess measuring of 5.5 ± 2.8 cm. Increased eosinophil levels were noted in 77% and 68% of the patients, whereas only 13%, 36%, and 19% showed decreased red blood cell counts, elevated white blood cell counts, and increased liver enzyme levels, respectively. Following three months of treatment with triclabendazole, 81% of patients achieved cure, while 19% (6 patients) remained uncured. The patients who did not respond to the initial treatment received an additional dose of triclabendazole (20 mg/kg body weight) and were monitored for another three months; all of these patients were cured.
conclusionsThe functional symptoms associated with fascioliasis include right hypochondriac pain, epigastric pain, fatigue, anorexia, weight loss, and fever. However, observable physical symptoms such as enlarged liver, jaundice, and yellow eyes are uncommon. Patients may exhibit liver lesions and an increase in eosinophils, but they rarely present with elevated liver enzymes or anemia. Treatment using triclabendazole is highly effective; however, an additional dose of triclabendazole is necessary to reach optimal effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.